Replies to post #365482 on Elite Pharmaceuticals Inc (ELTP)

[IB_]

"Is the CEO considering the development of a naltrexone-based antagonist ADF for CNS stimulants?": I am always thinking about our ADF antagonist and looking at all of our options.

"If so, what is the evidence that naltrexone can be used as an antagonist molecule for CNS stimulants?": No Answer

"Are there are any studies that can be cited that suggest this would be effective?": No Answer


"Are there any other drugs or experimental molecules that he is aware of that have shown this to be possible? What are they?": No Answer


..............................................

IB_

[The ELTP King]

Nice...

Submitted

Question for CC:

During the last several calls, the CEO has discussed using "our technology" for an ADF version of CNS stimulants. He said our technology is effective on all pleasure centers and "even works on alcohol", which suggests he is referring to naltrexone drug effects. Is the CEO considering the development of a naltrexone-based antagonist ADF for CNS stimulants? If so, what is the evidence that naltrexone can be used as an antagonist molecule for CNS stimulants? Are there are any studies that can be cited that suggest this would be effective? Are there any other drugs or experimental molecules that he is aware of that have shown this to be possible? What are they?

[The ELTP King]

***** Amid backlash from chronic pain sufferers, CDC drops hard thresholds from opioid guidance *****
February 10, 2022
https://www.usatoday.com/story/news/health/2022/02/10/cdcs-opioid-prescribing-guide-differs-new-existing-pain-sufferers/6719364001/


In a victory for pain experts, CDC tones down its opioid prescribing guidelines
February 10, 2022
https://www.statnews.com/2022/02/10/in-a-victory-for-pain-experts-cdc-tones-down-its-opioid-prescribing-guidelines/


CDC Moves To Relax Opioid Prescription Guidance
February 10, 2022
https://www.forbes.com/sites/carlieporterfield/2022/02/10/cdc-moves-to-relax-opioid-prescription-guidance/?sh=23fd6e9e9c47


CDC proposes opioid prescribing guidelines that give doctors more flexibility
February 10, 2022
https://thehill.com/policy/healthcare/593670-cdc-proposes-new-opioid-prescribing-guidelines-seeking-more-flexibility

[no2koolaid]

A worthy question. But not worded in a way that a CEO of a business, even a little business like Elite, could answer.

Now why is that?

Imagine for a moment Elite is working on an ANDA different in the ways that are inferred. Why would a CEO reveal answers that are likely the basis for product development? The answer can be found in another question - Why reveal the answers to questions others might be seeking? The very basis for competitive advantage is doing that which others cannot. It is quintessential VRIN when others cannot do what you can and business malpractice to give the competition the answers or even suggesting leads they are likely spending money to discover. Remember, time to market matters. As does early entry. Knowledge is a costly weapon and is not to be shared.

I trust that Elite will save their evidence for the FDA not the admiring public, and certainly not listeners to a CC who may or may not be investors and may or may not be seeking business intelligence...and that is not oxymoronic.

Once again, medical knowledge is one thing and investing in business another. But assuredly, both are very far from the knowledge needed to actually run a business effectively. For all the noise, it remains that Elite is profitable. In fact,

40 percent of small businesses are profitable, 30 percent break even and 30 percent are continually losing money. Here is the link... https://www.chamberofcommerce.org/small-business-statistics/

[The ELTP King]

Wasn't answered.

Nasrat threw your question in the garbage can.

Submitted

Question for CC:

During the last several calls, the CEO has discussed using "our technology" for an ADF version of CNS stimulants. He said our technology is effective on all pleasure centers and "even works on alcohol", which suggests he is referring to naltrexone drug effects. Is the CEO considering the development of a naltrexone-based antagonist ADF for CNS stimulants? If so, what is the evidence that naltrexone can be used as an antagonist molecule for CNS stimulants? Are there are any studies that can be cited that suggest this would be effective? Are there any other drugs or experimental molecules that he is aware of that have shown this to be possible? What are they?